Foghorn Therapeutics is dedicated to discovering and developing novel therapeutics for patients with cancer by targeting genetically determined dependencies within the chromatin regulatory system. The company's Gene Traffic Control platform is used to identify, validate, and drug targets within this system. Key research and development activities include preclinical studies, clinical trials, and biomarker discovery. The company is developing FHD-286, a small molecule inhibitor of BRG1 and BRM, for metastatic uveal melanoma and relapsed/refractory AML/MDS. They are also developing FHD-609, a protein degrader for BRD9, to treat synovial sarcoma. This segment aims to provide targeted treatments for cancers with high unmet medical needs, improving patient outcomes and quality of life. Strategic collaborations, such as those with Merck and Loxo Oncology, enhance the company's capabilities and expand its pipeline.

This segment focuses on the discovery and development of medicines that modulate gene expression through selectively targeting the chromatin regulatory system. Foghorn's proprietary Gene Traffic Control platform is central to this effort, enabling the identification and validation of novel drug targets. Research and development activities include the development of enzymatic inhibitors and protein degraders as selective modulators of BRM, as well as ARID1B selective modulators for ovarian, endometrial, colorectal, bladder, and gastric cancers. The goal is to correct abnormal gene expression in serious diseases, particularly in oncology. The company's approach offers a unique opportunity for therapeutic intervention, potentially leading to more effective and personalized treatments. This segment leverages cutting-edge biotechnology and precision medicine to address complex diseases with high unmet medical needs.